menu search

NSRGY / Nestle shares at two-year low as investors weigh Wegovy rollout

Nestle shares at two-year low as investors weigh Wegovy rollout
Nestle shares were under pressure on Friday as investors weighed the potential impact of Novo Nordisk's blockbuster weight-losing drug Wegovy and how it could reduce spending on food. Read More
Posted: Oct 6 2023, 05:41
Author Name: Reuters
Views: 112349

NSRGY News  

SJM or NSRGY: Which Is the Better Value Stock Right Now?

By Zacks Investment Research
October 27, 2023

SJM or NSRGY: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Food - Miscellaneous sector might want to consider either Smucker (SJM) or Nestle SA (NSRGY). But which of these t more_horizontal

Nestle explores 'companion' food products amid Ozempic and Wegovy's weight loss drug surge

By Proactive Investors
October 19, 2023

Nestle explores 'companion' food products amid Ozempic and Wegovy's weight loss drug surge

Nestle S.A. (OTC:NSRGF, VTX:NESN) is embarking on the development of "companion" products aimed at capitalizing on the growing popularity of weight lo more_horizontal

Nestle price hikes fail to bump up sales revenue

By Proactive Investors
October 19, 2023

Nestle price hikes fail to bump up sales revenue

Nestle S.A. (OTC:NSRGF, VTX:NESN) has reported a decline in sales revenue over the year so far as hefty price hikes on the back of growing inflation more_horizontal

Nestle works on new range of weight-loss drug companion products as sales miss estimates

By Market Watch
October 19, 2023

Nestle works on new range of weight-loss drug companion products as sales miss estimates

Nestle on Thursday posted worse-than-expected results for the first nine months of 2023 as the company's CEO said the firm is now working on a new ran more_horizontal

Nestle begins work on 'companion products' for weight loss drugs

By Reuters
October 19, 2023

Nestle begins work on 'companion products' for weight loss drugs

Nestle on Thursday said it has started work on products to "companion" weight loss drugs like Novo Nordisk's game-changing Wegovy, hoping to cash in o more_horizontal

Nestle: French Price Competition Could Be Impediment To Growth

By Seeking Alpha
October 12, 2023

Nestle: French Price Competition Could Be Impediment To Growth

Nestle's real internal growth has been negative, owing to pricing growth outpacing organic growth. Increasing price competition in the French market c more_horizontal

Nestle shares at two-year low as investors weigh Wegovy rollout

By Reuters
October 6, 2023

Nestle shares at two-year low as investors weigh Wegovy rollout

Nestle shares were under pressure on Friday as investors weighed the potential impact of Novo Nordisk's blockbuster weight-losing drug Wegovy and how more_horizontal

Nestle SA (NSRGY) Upgraded to Buy: Here's What You Should Know

By Zacks Investment Research
September 18, 2023

Nestle SA (NSRGY) Upgraded to Buy: Here's What You Should Know

Nestle SA (NSRGY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the more_horizontal


Search within

Pages Search Results: